Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Convertible Debt (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Convertible Debt readings, the most recent being $93.5 million for Q2 2025.

  • For the quarter ending Q2 2025, Convertible Debt changed 0.34% year-over-year to $93.5 million, compared with a TTM value of $93.5 million through Jun 2025, changed 0.34%, and an annual FY2024 reading of $93.3 million, changed 0.33% over the prior year.
  • Convertible Debt hit $93.5 million in Q2 2025 for Apellis Pharmaceuticals, roughly flat from $93.4 million in the prior quarter.
  • The five-year high for Convertible Debt was $386.5 million in Q2 2021, with the low at $92.7 million in Q3 2022.
  • Median Convertible Debt over the past 5 years was $93.3 million (2024), compared with a mean of $147.0 million.
  • The sharpest move saw Convertible Debt surged 167.12% in 2021, then crashed 51.13% in 2022.
  • Year by year, Convertible Debt stood at $189.0 million in 2021, then plummeted by 50.94% to $92.7 million in 2022, then increased by 0.32% to $93.0 million in 2023, then rose by 0.33% to $93.3 million in 2024, then grew by 0.17% to $93.5 million in 2025.
  • According to Business Quant data, Convertible Debt over the past three periods came in at $93.5 million, $93.4 million, and $93.3 million for Q2 2025, Q1 2025, and Q4 2024 respectively.